-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, Shandong Lukang Pharmaceutical's acarbose tablets are about to enter the approval process and are expected to become the company's next blockbuster oral hypoglycemic drug
.
In the past October, the company's dapagliflozin tablets were approved on the same day as Beijing Fuyuan Pharmaceutical, and there were no domestic generic drugs in the domestic market
.
.
In the past October, the company's dapagliflozin tablets were approved on the same day as Beijing Fuyuan Pharmaceutical, and there were no domestic generic drugs in the domestic market
.
Figure 1: Shandong Lukang Pharmaceutical Product Registration Progress
Source: NMPA official website
Acarbose is a super-large variety of oral hypoglycemic drugs.
In 2019, the terminal sales of China's urban public hospitals , county-level public hospitals, urban community centers, and township health centers (referred to as Chinese public medical institutions) exceeded 9 billion yuan.
, Is the historical peak
.
In 2019, the terminal sales of China's urban public hospitals , county-level public hospitals, urban community centers, and township health centers (referred to as Chinese public medical institutions) exceeded 9 billion yuan.
, Is the historical peak
.
After being included in the national procurement in 2020, the price cut caused a sharp decline in sales, leaving only about 4.
3 billion yuan.
However, it still occupies the second place in the TOP list of non-insulin hypoglycemic drugs for oral administration, and its market demand is still not to be underestimated
.
In terms of corporate competition, Bayer's half of the country is no longer guaranteed, and domestic high-end generic drugs are accelerating the replacement of original research drugs in the market
.
3 billion yuan.
However, it still occupies the second place in the TOP list of non-insulin hypoglycemic drugs for oral administration, and its market demand is still not to be underestimated
.
In terms of corporate competition, Bayer's half of the country is no longer guaranteed, and domestic high-end generic drugs are accelerating the replacement of original research drugs in the market
.
Figure 2: The current approval status of dapagliflozin tablets
Source: One-click search on Mi Nei.
com
com
Dapagliflozin is a new oral hypoglycemic drug developed by Bristol-Myers Squibb (which has been transferred to AstraZeneca).
It is the world's first sodium-glucose transporter 2 (SGLT2) inhibitor approved for marketing.
Sleecom's Dagelite net global sales are close to 2 billion U.
S.
dollars
.
It is the world's first sodium-glucose transporter 2 (SGLT2) inhibitor approved for marketing.
Sleecom's Dagelite net global sales are close to 2 billion U.
S.
dollars
.
In 2021H1, among the TOP20 non-insulin hypoglycemic agents for oral administration in public medical institutions in China, dapagliflozin rose to fourth place, with sales exceeding 900 million yuan
.
The product had only AstraZeneca's import approval document earlier, and it has entered the 2020 National Medical Insurance Negotiation Catalog.
In October this year, Donglukang Pharmaceutical and Beijing Fuyuan Pharmaceutical won the first domestic imitations
.
.
The product had only AstraZeneca's import approval document earlier, and it has entered the 2020 National Medical Insurance Negotiation Catalog.
In October this year, Donglukang Pharmaceutical and Beijing Fuyuan Pharmaceutical won the first domestic imitations
.
Source: NMPA official website, Mi Nei.
com database
com database
The review data statistics are as of November 15.
If there are any errors or omissions, please correct me
.
If there are any errors or omissions, please correct me
.
Recently, Shandong Lukang Pharmaceutical's acarbose tablets are about to enter the approval process and are expected to become the company's next blockbuster oral hypoglycemic drug
.
In the past October, the company's dapagliflozin tablets were approved on the same day as Beijing Fuyuan Pharmaceutical, and there were no domestic generic drugs in the domestic market
.
.
In the past October, the company's dapagliflozin tablets were approved on the same day as Beijing Fuyuan Pharmaceutical, and there were no domestic generic drugs in the domestic market
.
Figure 1: Shandong Lukang Pharmaceutical Product Registration Progress
Source: NMPA official website
Acarbose is a super-large variety of oral hypoglycemic drugs.
In 2019, the terminal sales of China's urban public hospitals , county-level public hospitals, urban community centers, and township health centers (referred to as Chinese public medical institutions) exceeded 9 billion yuan.
, Is the historical peak
.
In 2019, the terminal sales of China's urban public hospitals , county-level public hospitals, urban community centers, and township health centers (referred to as Chinese public medical institutions) exceeded 9 billion yuan.
, Is the historical peak
.
After being included in the national procurement in 2020, the price cut caused a sharp decline in sales, leaving only about 4.
3 billion yuan.
However, it still occupies the second place in the TOP list of non-insulin hypoglycemic drugs for oral administration, and its market demand is still not to be underestimated
.
In terms of corporate competition, Bayer's half of the country is no longer guaranteed, and domestic high-end generic drugs are accelerating the replacement of original research drugs in the market
.
3 billion yuan.
However, it still occupies the second place in the TOP list of non-insulin hypoglycemic drugs for oral administration, and its market demand is still not to be underestimated
.
In terms of corporate competition, Bayer's half of the country is no longer guaranteed, and domestic high-end generic drugs are accelerating the replacement of original research drugs in the market
.
Figure 2: The current approval status of dapagliflozin tablets
Source: One-click search on Mi Nei.
com
com
Dapagliflozin is a new oral hypoglycemic drug developed by Bristol-Myers Squibb (which has been transferred to AstraZeneca).
It is the world's first sodium-glucose transporter 2 (SGLT2) inhibitor approved for marketing.
Sleecom's Dagelite net global sales are close to 2 billion U.
S.
dollars
.
It is the world's first sodium-glucose transporter 2 (SGLT2) inhibitor approved for marketing.
Sleecom's Dagelite net global sales are close to 2 billion U.
S.
dollars
.
In 2021H1, among the TOP20 non-insulin hypoglycemic agents for oral administration in public medical institutions in China, dapagliflozin rose to fourth place, with sales exceeding 900 million yuan
.
The product had only AstraZeneca's import approval document earlier, and it has entered the 2020 National Medical Insurance Negotiation Catalog.
In October this year, Donglukang Pharmaceutical and Beijing Fuyuan Pharmaceutical won the first domestic imitations
.
.
The product had only AstraZeneca's import approval document earlier, and it has entered the 2020 National Medical Insurance Negotiation Catalog.
In October this year, Donglukang Pharmaceutical and Beijing Fuyuan Pharmaceutical won the first domestic imitations
.
Source: NMPA official website, Mi Nei.
com database
com database
The review data statistics are as of November 15.
If there are any errors or omissions, please correct me
.
If there are any errors or omissions, please correct me
.
Recently, Shandong Lukang Pharmaceutical's acarbose tablets are about to enter the approval process and are expected to become the company's next blockbuster oral hypoglycemic drug
.
In the past October, the company's dapagliflozin tablets were approved on the same day as Beijing Fuyuan Pharmaceutical, and there were no domestic generic drugs in the domestic market
.
.
In the past October, the company's dapagliflozin tablets were approved on the same day as Beijing Fuyuan Pharmaceutical, and there were no domestic generic drugs in the domestic market
.
Figure 1: Shandong Lukang Pharmaceutical Product Registration Progress
Medicine Medicine Medicine Source: NMPA official website
Acarbose is a super-large variety of oral hypoglycemic drugs.
In 2019, the terminal sales of China's urban public hospitals , county-level public hospitals, urban community centers, and township health centers (referred to as Chinese public medical institutions) exceeded 9 billion yuan.
, Is the historical peak
.
Hospital hospital hospitalIn 2019, the terminal sales of China's urban public hospitals , county-level public hospitals, urban community centers, and township health centers (referred to as Chinese public medical institutions) exceeded 9 billion yuan.
, Is the historical peak
.
After being included in the national procurement in 2020, the price cut caused a sharp decline in sales, leaving only about 4.
3 billion yuan.
However, it still occupies the second place in the TOP list of non-insulin hypoglycemic drugs for oral administration, and its market demand is still not to be underestimated
.
In terms of corporate competition, Bayer's half of the country is no longer guaranteed, and domestic high-end generic drugs are accelerating the replacement of original research drugs in the market
.
Enterprise business enterprise3 billion yuan.
However, it still occupies the second place in the TOP list of non-insulin hypoglycemic drugs for oral administration, and its market demand is still not to be underestimated
.
In terms of corporate competition, Bayer's half of the country is no longer guaranteed, and domestic high-end generic drugs are accelerating the replacement of original research drugs in the market
.
Figure 2: The current approval status of dapagliflozin tablets
Source: One-click search on Mi Nei.
com
com
Dapagliflozin is a new oral hypoglycemic drug developed by Bristol-Myers Squibb (which has been transferred to AstraZeneca).
It is the world's first sodium-glucose transporter 2 (SGLT2) inhibitor approved for marketing.
Sleecom's Dagelite net global sales are close to 2 billion U.
S.
dollars
.
It is the world's first sodium-glucose transporter 2 (SGLT2) inhibitor approved for marketing.
Sleecom's Dagelite net global sales are close to 2 billion U.
S.
dollars
.
In 2021H1, among the TOP20 non-insulin hypoglycemic agents for oral administration in public medical institutions in China, dapagliflozin rose to fourth place, with sales exceeding 900 million yuan
.
The product had only AstraZeneca's import approval document earlier, and it has entered the 2020 National Medical Insurance Negotiation Catalog.
In October this year, Donglukang Pharmaceutical and Beijing Fuyuan Pharmaceutical won the first domestic imitations
.
.
The product had only AstraZeneca's import approval document earlier, and it has entered the 2020 National Medical Insurance Negotiation Catalog.
In October this year, Donglukang Pharmaceutical and Beijing Fuyuan Pharmaceutical won the first domestic imitations
.
Source: NMPA official website, Mi Nei.
com database
Source: NMPA official website, Mi Nei. com database
com database
The review data statistics are as of November 15.
If there are any errors or omissions, please correct me
.
If there are any errors or omissions, please correct me
.
